Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg names Admiral among top picks in European insurance

(Sharecast News) - Berenberg analysts have named UK-listed motor insurer Admiral among their top picks in the European insurance sector. In a research note hailing the upside potential of the sector, the broker said rising free cash flow, operating profit growth and increasing top-line momentum are three key reasons to buy insurers across the board.

"Our positive outlook is supported by positive updates from the insurers we cover during our pre-close calls, when we were reminded of the sector's known strong trends, as well as the readacross from the Q1 2025 results of Travelers," Berenberg said.

"Our top picks remain Admiral, Allianz, AXA, NN Group and SCOR, to which we could also add Phoenix among the UK life insurers and Swiss Re among the larger reinsurers."

For Admiral specifically, Berenberg said the current share price - despite having gained 20% so far this year - still offers an "attractive opportunity to acquire a quality company at a discount".

"Q1 market pricing data indicates price deflation is slowing and with Aviva's acquisition of Direct Line and Ageas's Esure takeover, the sector looks to be consolidating at pace. The market should be more rational as a result, we believe," the broker said.

Berenberg expects Admiral's earnings per share growth to average 5% between 2025 and 2027, and the company's dividend to yield 6-7%.

The stock was up around 1% at 3,236p by 1335 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.